GI Dynamics to start pivotal US trial of EndoBarrier
31 October, 2012 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has got the all-clear from the FDA to commence a 25-site pivotal trial of EndoBarrier in type 2 diabetes in the US.
Phosphagenics licenses TPM to Indian pharma
30 October, 2012 by Dylan Bushell-EmblingIndia's Agila Specialties has arranged to license Phosphagenics' (ASX:POH) TPM drug delivery platform, and use it to create an injectable antibiotic product.
AusBiotech 2012 special feature: Big deals
30 October, 2012 by Dylan Bushell-EmblingBe it through major licensing or development deals, domestic and international expansion, mergers and spin-offs or potentially game-changing research, biotechnology companies across Australia have been making waves in recent months.
AusFoodTech Symposium 2012 to feature Dr Andrew Powell
30 October, 2012 by AusBiotechThe second AusFoodtech symposium, to be held on Friday in Melbourne, will feature keynote speaker, Dr Andrew Powell, Chief Executive Officer of Asia BioBusiness.
Benitec completes Tacere acquisition
30 October, 2012 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has completed the acquisition of US-based RNA interference therapeutics discovery company Tacere Therapeutics.
Melbourne Uni cuts deal with Janssen-Cilag to research respiratory infection drug
29 October, 2012 by Dylan Bushell-EmblingThe University of Melbourne and Janssen-Cilag have signed a collaboration agreement covering research into drug candidates for acute respiratory infections.
Starpharma technology improves anti-cancer drug 40-fold
29 October, 2012 by Dylan Bushell-EmblingAnimal trials of Starpharma's (ASX:SPL) dendrimer-docetaxel chemotherapy product show the formulation is potentially far more effective at targeting tumours than the conventional formula.
AusBiotech 2012 special feature: Found in translation
29 October, 2012 by Tim DeanHere are five ways that are currently being discussed that could transform the commercialisation of medical research in Australia.
Abraxane performs well in metastatic melanoma
26 October, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has revealed some positive results from a phase III trial of nanoparticle chemotherapy Abraxane in metastatic melanoma.
Pharmaxis' Bronchitol to get NHS listing in UK
26 October, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has received the final approval required to have its Bronchitol cystic fibrosis treatment cleared for reimbursement by the UK National Health Service.
Have you registered for biotech’s industry event of the year?
25 October, 2012 by AusBiotechProminent biotechnology individuals from across Australia and around the world will join the conference for agenda-setting programs, world-class networking and partnering opportunities, and over 150 industry-leading speakers in more than 30 sessions.
Agenix opens new avenues with diagnostics deal
25 October, 2012 by Dylan Bushell-EmblingAgenix (ASX:AGX) has arranged to license a diagnostic device platform from Tyrian Diagnostics in a share swap deal.
R&D Tax Incentive remains untouched as tax reform stalls
25 October, 2012 by Tim DeanThe government’s Business Tax Working Group has failed to reach agreement on how to fund a cut in corporate tax, leaving the R&D Tax Incentive as is.
Avexa's antibiotic storms lab tests
24 October, 2012 by Dylan Bushell-EmblingAvexa's (ASX:AVX) anti-bacterial compound AVX13616 has performed well in lab tests conducted by licensee Valevia Pharmaceuticals.
Australian biotechs significantly outperforming ASX and Nasdaq
24 October, 2012 by Tim DeanThe Australian life science index is known for its volatility, but over the past decade it has outperformed the All Ordinaries and the Nasdaq by considerable margins.
